What’s new

• Maharashtra FDA seized stock of Enerzal during warehouse inspections.
• Regulator collected samples for examination over allegations of misbranding.
• FDC told stock exchanges it sees no material financial impact from the seizure.

Why it matters

This is a direct regulatory action against a flagship consumer product. While FDC downplays the immediate financial hit, a confirmed misbranding finding could force product recalls, costly label changes, and administrative penalties. It signals increased regulatory scrutiny on marketing claims in the fast-moving consumer health space.

What we’re watching

• The final examination order from Maharashtra FDA, which will determine the severity.
• Whether FDC's legal challenge succeeds or fails.
• Impact on Enerzal sales if the product remains under regulatory cloud.

The full read

The Maharashtra FDA has seized stock of Enerzal, a flagship electrolyte brand from FDC Ltd., during warehouse inspections in Nagpur and Chhatrapati Sambhaji Nagar. The regulator collected samples over allegations of misbranding, a charge that carries real operational and reputational risk if proven. FDC told exchanges on June 4 it sees no material financial hit for now, but the final examination order is pending. A adverse finding would likely force costly labeling changes or a recall, and it puts FDC's broader consumer-health portfolio under a brighter regulatory light. The company's plan to pursue legal recourse is a defensive posture. What matters is the finding itself.

Primary source: BSE · NSE

What’s new

• Q4 consolidated revenue rose 18.9% YoY to ₹585 cr, with net profit doubling to ₹103 cr.
• US formulations revenue surged 283% to ₹39 cr; EBITDA margin expanded to 18.2% from 11%.
• Full-year revenue was up just 3% to ₹2,171 cr; net profit grew 5.5% to ₹281 cr.

Why it matters

The quarter showed what FDC can do when its US business fires. But a 3% full-year revenue growth, with domestic formulations flat, shows the core business remains stuck. The Q4 beat doesn't change the annual story.

What we’re watching

• Whether the US growth is sustained or a one-off from the fluconazole launch.
• Domestic formulation trends in Q1 FY27.
• Margin durability at the new 18.2% EBITDA level.

The full read

FDC closed FY26 with a quarter that showed what the US business can deliver. Q4 consolidated revenue of ₹585 crore rose 18.9% year-on-year, and net profit of ₹103 crore more than doubled. The engine was US formulations, which surged 283% to ₹39 crore after the company received a US FDA approval for fluconazole tablets. EBITDA margin expanded sharply to 18.2% from 11% a year prior. But zoom out, and the year was flat. Full-year revenue of ₹2,171 crore grew just 3%, and net profit of ₹281 crore was up 5.5%, as domestic formulations remained sluggish. The Q4 numbers are a clean beat. The annual numbers are a reminder that the core business hasn't found a second gear.

Primary source: BSE · NSE

What’s new

• FY26 standalone revenue reached ₹2,126.33 crore, a 2.7% increase.
• Q4 standalone revenue rose 17% YoY, with profit surging 122%.
• Results include a one-time ₹20.79 crore charge for Labour Code changes.

Why it matters

The annual performance met expectations, but the sharp Q4 recovery suggests better momentum heading into the new fiscal year. The quarterly figures are derived from the difference between audited annual results and nine-month unaudited data.

What we’re watching

• Whether the Q4 profit gains persist in FY27.
• Management commentary on the impact of Labour Code changes.
• Sustainability of the 17% revenue growth seen in the final quarter.

The full read

FDC Ltd. finished FY26 with a 2.7% rise in standalone revenue to ₹2,126.33 crore and a 4.5% increase in net profit to ₹285.92 crore. These figures include a ₹20.79 crore one-time charge linked to Labour Code adjustments. While the annual growth was modest, the final quarter provided a clear lift. Standalone revenue for Q4 climbed 17% year-on-year, and profit surged 122%. Because these quarterly figures are calculated as the difference between audited annual results and unaudited nine-month data, they are a balancing figure. The auditors provided an unmodified opinion on the financials. With the core data already known, this filing is a routine compliance step that confirms the company's performance remains within expected ranges.

Primary source: BSE · NSE

What’s new

• Annual revenue grew 2.7% while profit rose 4.5% for FY26.
• Q4 revenue climbed 17% and profit jumped 122% compared to the same period last year.
• The company booked a one-time exceptional charge of ₹20.79 cr for labour code changes.

Why it matters

The quarterly surge provides a positive close to an otherwise flat fiscal year. Investors should note the impact of the ₹20.79 cr exceptional charge, which weighed on the annual bottom line.

What we’re watching

• Whether the Q4 momentum carries into the new fiscal year.
• Management commentary on the impact of labour code adjustments.
• Sustainability of the recent profit gains.

The full read

FDC closed FY26 with mixed results. Annual revenue grew by a modest 2.7% and profit by 4.5%.

Then came the final quarter. Q4 revenue climbed 17% and profit surged 122% year-on-year, even after accounting for a one-time exceptional charge of ₹20.79 crore related to labour code changes. The auditors provided an unmodified opinion on the financials. This was a routine earnings disclosure, and the market had largely anticipated these figures. There were no unexpected strategic shifts or material surprises.

It is a late-stage recovery. The primary takeaway is a strong finish to a year of otherwise slow growth.

Primary source: BSE · NSE